Pixium Vision to attend BIOMED EVENT® by Invest Securities on January 26, 2022Antoine Balavoine2022-01-06T07:31:31+01:00January 6th, 2022|
Pixium Vision to attend 11th Annual LifeSci Partners Corporate Access EventAntoine Balavoine2021-12-14T07:00:57+01:00December 14th, 2021|
Pixium Vision gaining confidence in execution timeline of the PRIMAvera pivotal trial following first patient implantation in the UKAntoine Balavoine2021-12-09T16:44:15+01:00December 8th, 2021|
Pixium Vision to present at BTIG’s Ophthalmology DayAntoine Balavoine2021-11-25T07:48:42+01:00November 25th, 2021|
Pixium Vision to present at the 3rd edition of Investir Day in Paris, November 2021Antoine Balavoine2021-11-08T07:46:02+01:00November 8th, 2021|
Pixium Vision announces its cash position at 30 September 2021Antoine Balavoine2021-10-22T11:54:35+02:00October 22nd, 2021|
Pixium Vision announces positive long-term follow-up scientific data on PRIMA implant from Prima System French feasibility studyAntoine Balavoine2021-10-13T02:53:51+02:00October 13th, 2021|
Pixium Vision to attend the 8th Annual Healthtech Investment Forum on October 5 & 6, 2021Antoine Balavoine2021-10-04T19:06:55+02:00October 4th, 2021|
Implantation of first patient in GermanyAntoine Balavoine2021-09-23T07:34:31+02:00September 23rd, 2021|
Pixium Vision expands collaboration with Stanford University on next generation Prima System implantsAntoine Balavoine2021-09-08T19:57:44+02:00September 8th, 2021|
Geographical expansion of PRIMAvera European pivotal study with opening of first UK clinical site at Moorfields Eye HospitalAntoine Balavoine2021-08-13T12:52:18+02:00August 13th, 2021|
Pixium Vision announces its financial results for H1 2021 and provides a business updateAntoine Balavoine2021-07-27T11:22:02+02:00July 27th, 2021|
Pixium Vision announces a capital increase of approximately €8 million through a private placementAntoine Balavoine2021-07-14T09:31:42+02:00July 13th, 2021|